Neurocrine Biosciences, Inc. $NBIX Stock Holdings Raised by Swedbank AB

Swedbank AB increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 17.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 503,502 shares of the company’s stock after purchasing an additional 73,805 shares during the period. Swedbank AB owned 0.51% of Neurocrine Biosciences worth $63,285,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. grew its position in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. WPG Advisers LLC bought a new position in Neurocrine Biosciences during the first quarter worth $32,000. Smallwood Wealth Investment Management LLC acquired a new position in Neurocrine Biosciences in the first quarter worth $34,000. SVB Wealth LLC bought a new stake in Neurocrine Biosciences during the first quarter valued at $35,000. Finally, Golden State Wealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 116.9% during the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after purchasing an additional 214 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In other news, insider Jude Onyia sold 59,819 shares of the firm’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total value of $7,803,986.74. Following the completion of the sale, the insider owned 18,289 shares of the company’s stock, valued at $2,385,982.94. This trade represents a 76.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Kevin Charles Gorman sold 106,322 shares of the company’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the transaction, the director directly owned 514,596 shares in the company, valued at $65,050,080.36. The trade was a 17.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 186,960 shares of company stock worth $23,955,553 over the last quarter. Corporate insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the subject of a number of analyst reports. Royal Bank Of Canada boosted their target price on shares of Neurocrine Biosciences from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. UBS Group raised their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday, July 9th. Guggenheim lifted their target price on Neurocrine Biosciences from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Wedbush increased their price target on Neurocrine Biosciences from $137.00 to $141.00 and gave the stock an “outperform” rating in a research note on Thursday, July 31st. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.26.

Neurocrine Biosciences Trading Up 2.1%

NBIX stock opened at $145.66 on Friday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $154.61. The firm has a 50-day moving average of $135.03 and a two-hundred day moving average of $121.85. The firm has a market capitalization of $14.45 billion, a PE ratio of 43.09, a P/E/G ratio of 1.03 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The business had revenue of $687.50 million for the quarter, compared to analyst estimates of $653.09 million. During the same quarter in the previous year, the business earned $1.63 earnings per share. The firm’s revenue was up 16.5% compared to the same quarter last year. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.